2023-508411-23-00招募中2 期
PREDIX HER2 - Neoadjuvant response-guided treatment of HER2 positive breast cancer. Part of a platform of translational phase II trials based on molecular subtypes
Karolinska University Hospital9 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2023年10月2日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 200
- 试验地点
- 9
- 主要终点
- Pathological objective response to primary medical treatment
研究概览
简要总结
Evaluate the impact of response-guided treatment on objective response and long-term outcome.
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •Written informed consent
- •Patients with breast cancer confirmed by histology, characterized by immunohistochemistry for ER, PR, HER2 and proliferation marker
- •Tumor and blood samples available. HER2 type confirmed by genomic profiling using Next-Generation Sequencing.
- •Age 18 years or older. Elderly patients in condition adequate for planned therapy
- •Primary breast cancer >20mm in diameter and/or verified lymph node metastases
- •Adequate bone marrow, renal, hepatic and cardiac functions and no other uncontrolled medical or psychiatric disorders
- •ECOG performance status 0-1
- •Primary breast cancer as defined in p. 5 plus at most 2 morphologically characterized well-defined distant metastases accessible for stereotactic radiotherapy, provided that this treatment is available.
排除标准
- •Distant metastases, including node metastases in the contralateral thoracic region or in the mediastinum
- •Other malignancy diagnosed within the last five years, except for radically treated basal or squamous cell carcinoma of the skin or CIS of the cervix
- •Patients in child-bearing age without adequate contraception
- •Pregnancy or lactation
- •Uncontrolled hypertension, heart, liver, kidney related or other medical or psychiatric disorders.
结局指标
主要结局
Pathological objective response to primary medical treatment
Pathological objective response to primary medical treatment
次要结局
- Clinical/radiological objective response during neoadjuvant treatment
- Morphological, functional and biological characteristics of tumors exposed to cytotoxic and targeted treatment of early breast cancer
- Event-free survival (EFS), invasive disease-free survival (IDFS), distant disease-free survival (DDFS), breast cancer-specific survival (BCSS) and overall survival (OS)
- Safety
- Quality of life
- Frequency of breast-conserving surgery
研究者
Thomas Hatschek
Scientific
Karolinska University Hospital
研究点 (9)
Loading locations...
相似试验
进行中（未招募）
1 期
PREDIX HER2 - preoperative treatment of HER2 positive breast cancerPrimary breast cancerMedDRA version: 20.0Level: PTClassification code: 10006201Term: Breast cancer stage III Class: 100000004864MedDRA version: 21.1Level: LLTClassification code: 10006188Term: Breast cancer female NOS Class: 10029104MedDRA version: 20.0Level: PTClassification code: 10006200Term: Breast cancer stage II Class: 100000004864MedDRA version: 21.1Level: LLTClassification code: 10006191Term: Breast cancer male NOS Class: 10029104CTIS2023-508411-23-00Karolinska University Hospital200
进行中（未招募）
1 期
PREDIX HER2 - preoperative treatment of HER2 positive breast cancerEUCTR2014-000808-10-SEKarolinska University Hospital200
招募中
2 期
Study of neoadjuvant patritumab deruxtecan with or without endocrine therapy in previously untreated patients – VALENTINE trial2023-503403-28-00Solti Group120
进行中（未招募）
2/3 期
Single arm phase 2 trial of neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a standard chemotherapy-sparing approach to curative-intent treatment – SHAMROCK study2024-516582-36-00Cancer Trials Ireland77
招募中
3 期
Optimizing neoadjuvant systemic treatment in HER2 positive breast cancer - the TRAIN-2 studyHER2 positive breast cancer10006291breast cancerNL-OMON45049BOOG Study Center (onderzoeksgroep zonder winstoogmerk)430